Use of Antineoplastic Agents in Patients with Cancer Who Have HIV/AIDS

Overview

Journal Lancet Oncol

Specialty Oncology

Date 2011 May 17

PMID 21570912

Citations 48

Authors

Michelle A Rudek

Charles Flexner

Richard F Ambinder

Affiliations

Soon will be listed here.

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

Citing Articles

Patients with colorectal cancer combined with HIV had a worse overall survival after surgery: a meta-analysis.

Yang W, Zhou X, He G Front Oncol. 2025; 15:1440105.

PMID: 39944832 PMC: 11813759. DOI: 10.3389/fonc.2025.1440105.

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M J Clin Oncol. 2024; 43(4):432-442.

PMID: 39356983 PMC: 11779594. DOI: 10.1200/JCO.24.00640.

Navigating the Nexus: HIV and Breast Cancer-A Critical Review.

Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S Int J Mol Sci. 2024; 25(6).

PMID: 38542195 PMC: 10970700. DOI: 10.3390/ijms25063222.

Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.

Bibas M Mediterr J Hematol Infect Dis. 2024; 16(1):e2024015.

PMID: 38468838 PMC: 10927196. DOI: 10.4084/MJHID.2024.015.

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.

Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A Lancet Haematol. 2023; 10(8):e624-e632.

PMID: 37532416 PMC: 10859222. DOI: 10.1016/S2352-3026(23)00157-6.

References

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J . Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999; 27(8):895-901. View

Miller A, Murry D, Owzar K, Hollis D, Kennedy E, Abou-Alfa G . Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009; 27(11):1800-5. PMC: 2668705. DOI: 10.1200/JCO.2008.20.0931. View

Decker C, Laitinen L, Bridson G, Raybuck S, Tung R, Chaturvedi P . Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci. 1998; 87(7):803-7. DOI: 10.1021/js980029p. View

Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F . Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther. 2007; 83(4):601-6. DOI: 10.1038/sj.clpt.6100330. View

King J, Acosta E . Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet. 2006; 45(7):665-82. DOI: 10.2165/00003088-200645070-00003. View

Zucker S, Qin X, Rouster S, Yu F, Green R, Keshavan P . Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001; 98(22):12671-6. PMC: 60112. DOI: 10.1073/pnas.231140698. View

Lim M, Min S, Eron J, Bertz R, Robinson M, Gaedigk A . Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004; 36(5):1034-40. DOI: 10.1097/00126334-200408150-00006. View

Knox T, Oleson L, von Moltke L, Kaufman R, Wanke C, Greenblatt D . Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr. 2009; 49(4):358-68. DOI: 10.1097/qai.0b013e31818c7efe. View

Faucette S, Zhang T, Moore R, Sueyoshi T, Omiecinski C, LeCluyse E . Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2006; 320(1):72-80. PMC: 4091905. DOI: 10.1124/jpet.106.112136. View

10.

Mouscadet J, Arora R, Andre J, Lambry J, Delelis O, Malet I . HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. J Mol Recognit. 2009; 22(6):480-94. DOI: 10.1002/jmr.970. View

11.

Liu B, Juurlink D . Drugs and the QT interval - caveat doctor. N Engl J Med. 2004; 351(11):1053-6. DOI: 10.1056/NEJMp048192. View

12.

Greenblatt D, von Moltke L, Daily J, Harmatz J, Shader R . Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol. 1999; 19(4):293-6. DOI: 10.1097/00004714-199908000-00001. View

13.

Kharasch E, Mitchell D, Coles R, Blanco R . Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008; 52(5):1663-9. PMC: 2346649. DOI: 10.1128/AAC.01600-07. View

14.

Hyland R, Dickins M, Collins C, Jones H, Jones B . Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008; 66(4):498-507. PMC: 2561101. DOI: 10.1111/j.1365-2125.2008.03198.x. View

15.

Robertson S, Maldarelli F, Natarajan V, Formentini E, Alfaro R, Penzak S . Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008; 49(5):513-9. PMC: 9036313. DOI: 10.1097/QAI.0b013e318183a425. View

16.

Kotb R, Vincent I, Dulioust A, Peretti D, Taburet A, Delfraissy J . Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol. 2006; 76(3):269-71. DOI: 10.1111/j.0902-4441.2005.t01-1-EJH2435.x. View

17.

Belanger A, Caron P, Harvey M, Zimmerman P, Mehlotra R, Guillemette C . Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009; 37(9):1793-6. PMC: 2729325. DOI: 10.1124/dmd.109.027706. View

18.

Nallani S, Goodwin B, Buckley A, Buckley D, Desai P . Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol. 2004; 54(3):219-29. DOI: 10.1007/s00280-004-0799-9. View

19.

Vourvahis M, Kashuba A . Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy. 2007; 27(6):888-909. DOI: 10.1592/phco.27.6.888. View

20.

Taylor S, Boffito M, Khoo S, Smit E, Back D . Stopping antiretroviral therapy. AIDS. 2007; 21(13):1673-82. DOI: 10.1097/QAD.0b013e3281c61394. View